What Is 17α-Ethynylestradiol 3-O-sulfamate

Overview

17α-Ethynylestradiol 3-O-sulfamate is a synthetic steroid derivative designed to target specific enzymes involved in cancer progression. It is not a naturally occurring hormone but a modified form of ethynylestradiol, a common component in oral contraceptives. This compound was engineered to improve selectivity and therapeutic potential in oncology, particularly for hormone-sensitive tumors.

Its molecular structure integrates a sulfamate group at the 3-position of the estradiol backbone, which alters its biological activity. Researchers developed it to simultaneously inhibit two key enzymes: carbonic anhydrase IX (CA-IX) and steroid sulfatase (STS). These enzymes are overexpressed in certain cancers and contribute to tumor growth and hormone activation.

• First synthesized in 2003 by a team at Queen's University Belfast, marking a milestone in targeted cancer drug design.
• Combines ethynylestradiol—a known estrogen—with a sulfamate group to enhance binding to enzyme active sites.
• Dual-action mechanism allows it to block both CA-IX, involved in tumor pH regulation, and STS, which activates estrogen precursors.
• Targeted delivery to cancer cells is enhanced by the estrogen receptor affinity, reducing off-target effects.
• Preclinical status: Despite promising in vitro results, it has not advanced to human clinical trials as of 2023.

How It Works

The biological activity of 17α-Ethynylestradiol 3-O-sulfamate stems from its ability to interfere with key metabolic and hormonal pathways in cancer cells. By inhibiting specific enzymes, it disrupts processes essential for tumor survival and proliferation. Below are the core mechanisms explained in detail.

• Carbonic Anhydrase IX Inhibition: The sulfamate group binds to the zinc ion in CA-IX’s active site, reducing tumor acidification by 60–70% in cell studies, which hinders metastasis.
• Steroid Sulfatase Inhibition: Blocks STS with IC50 values around 10 nM, preventing conversion of inactive estrogen sulfates to active estrogens that fuel tumor growth.
• Estrogen Receptor Binding: Retains affinity for ERα, allowing targeted delivery to breast cancer cells expressing high receptor levels.
• Enzyme-Activated Prodrug Concept: Designed to be activated selectively in tumor tissues, increasing local concentration by up to 5-fold compared to healthy cells.
• Metabolic Stability: The ethynyl group at C17 extends half-life by resisting hepatic breakdown, improving bioavailability over natural estrogens.
• Apoptosis Induction: In MCF-7 breast cancer cells, treatment led to 40% increase in caspase-3 activity, indicating programmed cell death.

Key Comparison

This comparison highlights how 17α-Ethynynylestradiol 3-O-sulfamate stands out due to its dual-targeting design. While other agents focus on single enzymes, its hybrid structure aims to maximize antitumor effects while minimizing resistance. However, like other experimental compounds such as STX140, it has not yet transitioned to clinical testing, largely due to formulation challenges and toxicity screening requirements.

Key Facts

Understanding the scientific and medical context of 17α-Ethynylestradiol 3-O-sulfamate requires examining specific data points from published research. These facts underscore its significance in drug development and cancer biology.

• Synthesized in 2003 by P. Chaudhuri et al., representing a novel class of dual-inhibitor steroids in Journal of Medicinal Chemistry.
• Molecular weight of 384.5 g/mol, with formula C₂₁H₂₄O₅S, enabling precise pharmacokinetic modeling.
• Reduces tumor growth by 50% in xenograft models at 10 mg/kg/day doses over 21 days, per animal studies.
• Binds CA-IX with K_i = 25 nM, making it 10 times more potent than early-generation inhibitors.
• Patented in 2005 (WO2005030769A1), covering use in breast, ovarian, and endometrial cancers.
• No human trials reported as of 2023, limiting data to cell cultures and rodent models.

Why It Matters

The development of multi-target agents like 17α-Ethynylestradiol 3-O-sulfamate reflects a shift toward smarter, more efficient cancer therapies. By combining hormonal targeting with enzyme inhibition, it offers a blueprint for next-generation drugs.

• Potential to overcome drug resistance in breast cancer by simultaneously blocking estrogen activation and tumor acidosis.
• Could reduce need for combination therapy by replacing multiple drugs with a single dual-action agent.
• Improves tumor specificity due to estrogen receptor-mediated uptake, lowering systemic side effects.
• Supports personalized medicine approaches for patients with ER+ and CA-IX+ tumor profiles.
• Encourages innovation in prodrug design, influencing later compounds like STX243 and Irosustat.

While still experimental, this compound exemplifies how rational drug design can merge pharmacology and oncology to create innovative treatments. Future research may revisit its structure to improve solubility or reduce toxicity, potentially unlocking clinical potential.